Importance Multiple sclerosis produces neurological impairments that are variable in duration,
severity and quality. Speech is frequently impaired, resulting in decreased communication …

Objective: To investigate the potential links between thinning of retinal ganglion cell axons
in eyes of patients with multiple sclerosis (MS) without past optic neuritis (ON) and MS-related …

Background: The risk factors for conversion from relapsing-remitting to secondary progressive
multiple sclerosis remain highly contested. Objective: The aim of this study was to …

Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—relapsing-remitting,
secondary progressive, and primary progressive—for patient care, research, …

… Anneke van der Walt has served on scientific advisory boards, received travel support and
speaker’s honoraria from Biogen, Merck, Novartis, and Roche. She is supported by funding …

Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for
severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive …

Background Treatment with natalizumab once every 4 weeks is approved for patients with
relapsing-remitting multiple sclerosis, but is associated with a risk of progressive multifocal …

Objective To test the hypothesis that immunotherapy prevents long-term disability in
relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. …

… van der Walt has received honoraria and unrestricted research funding from Novartis, Biogen…
van der Mei and GS do Olival have no relevant conflicts of interests to disclose. M. Magyari …

In this consensus statement, we provide updated recommendations on multiple sclerosis (MS)
management during the COVID-19 crisis and the post-pandemic period applicable to …